😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!) 🤝Well-aligned with @easlnews.bsky.social CPGs 😟Reimbursement currently restricted to semaglutide for T2DM 🤔Reimbursement in your country? 🖇️: rdcu.be/eLAde #LiverSky @georg-semmler.bsky.social

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s) 👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3 🖇️ for explanation: authors.elsevier.com/sd/article/S...

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s) 👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3 🖇️ for explanation: authors.elsevier.com/sd/article/S...

@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension 👀 at our auditorium 🙏 incredible hospitality 👉 See our 🇯🇵 friends at Baveno VIII

I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation. A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure. Rest in peace, Jaime

Monitoring resmetirom by LSM - asking for the moon? Oftentimes mentioned but even more often forgotten: ❗️Random variation of LSM by VCTE exceeds 25% 👉🔽 LSM >25% often by chance, same for 'unchanged' or increases 👉No substitute for clinical judgement #LiverSky @georg-semmler.bsky.social 🔗👇

How often do u get asked to “clear” patients w/cirrhosis for surgery? How about “just” being on board? #liversky Well, if u want to get on board, here is your next read 👇🏼 Guidelines on abdominal surgery in patients w/cirrhosis @jhepatology.bsky.social www.journal-of-hepatology.eu/article/S016...

📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS! 🤝 See you at 10:30 Erlinger Room! @bavenocoop.bsky.social #LiverSky

Journal of Hepatology@jhepatology.bsky.social · last yr.

🆕CPG in press❕ EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease Find it here👉https://bit.ly/3GM9EEB #LiverSky @easlnews.bsky.social

👏 Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation. Chapeau! What a wonderful person! #LiverSky

Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event. 🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky

‼️Following first hepatic decompensation, patients with severe #AATD have a higher risk of complications vs. other aetiologies 👉Early listing for liver transplantation. #LiverSky 🔗https://doi.org/10.1016/j.jhepr.2024.101308 @easlnews.bsky.social @jhepatology.bsky.social

Have you ever screened 25 patients for a single trial and randomized nearly as many? Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ... #LiverSky @bavenocoop.bsky.social

Conversation with the Customs employee at the airport when entering the U.S. for a 1-day meeting: When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋

@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go! 👍 103 members watching online 👉 High interest in designing clinical studies on PH. #liversky

I had the privilege to visit two top liver destinations in 🇪🇺 in the last couple of days - 🙏 enormous hospitality 🇨🇭Bern @docberza.bsky.social et al 🇮🇹Padova Alberto Zanetto et al 👀Summary slides attached! #liversky

Challenge for #liversky : Monitoring regression/progression on resmetirom & deciding on alternative treatments ▶️ AASLD provided guidance ▶️ We commented on the role of LSM: doi.org/10.1097/HEP.... ‼️ Random variation in LSM >25% ‼️ Consider overall medical benefit (e.g., GLP-1)

👋 Bluesky 📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond @docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports 🔗https://doi.org/10.1016/j.jhepr.2024.101300